# Bob Schafer

> Bob Schafer, PhD, is the CEO of Lumos Labs, the company behind Lumosity, the world's largest brain training platform with over 100 million users. A Stanford-trained neuroscientist with postdoctoral work at MIT, Schafer founded Prophecy Sciences (YC W13) before joining Lumos Labs via acquihire in 2015. He rose from Head of Research to Chief Science Officer to President of Lumosity DTx before being named CEO in May 2023. Under his leadership, Lumos Labs achieved FDA 510(k) clearance in December 2025 for LumosityRx (marketed as Prismira), the first prescription digital therapeutic for attention improvement in adults with ADHD — validated by a 500-participant randomized controlled trial.

- **Role:** Chief Executive Officer at Lumos Labs (Lumosity)
- **Organizations:** Lumos Labs, Lumosity, Lumosity DTx, Prophecy Sciences
- **Nationality:** American
- **Education:** PhD in Neuroscience, Stanford University, Postdoctoral Research, MIT
- **Known for:** Led FDA 510(k) clearance of LumosityRx (Prismira) — first prescription digital therapeutic for adult ADHD — December 2025, Founded and led Prophecy Sciences through Y Combinator (W13), applying neuroscience and biosignals to workplace performance assessment, Published original neuroscience research in Science and Neuron — two of the most prestigious scientific journals

## Career timeline

- **pre-2012** — Completed PhD in Neuroscience at Stanford University and postdoctoral research at MIT; published original research in Science and Neuron
- **2012** — Founded Prophecy Sciences, a neuroscience startup applying biosignals and machine learning to hiring and team assessment
- **2013** — Prophecy Sciences enters Y Combinator (W13); company launches publicly using biometric headsets, eye tracking, and cognitive games for talent screening
- **2015** — Lumos Labs acquihires Prophecy Sciences; Schafer joins Lumos Labs as Head of Research
- **2019** — Promoted to Chief Science Officer (CSO) of Lumos Labs
- **2021** — Named President of Lumosity DTx, the company's medical products division focused on digital therapeutics
- **2023** — Appointed Chief Executive Officer of Lumos Labs in May; Krishna Kakarala transitions to Executive Chairman
- **2025** — FDA grants 510(k) clearance for LumosityRx (Prismira) — first prescription digital therapeutic for attention improvement in adults with ADHD, validated by the GAMES Study

## Achievements

- Led FDA 510(k) clearance of LumosityRx (Prismira) — first prescription digital therapeutic for adult ADHD — December 2025
- Founded and led Prophecy Sciences through Y Combinator (W13), applying neuroscience and biosignals to workplace performance assessment
- Published original neuroscience research in Science and Neuron — two of the most prestigious scientific journals
- Built and led Lumosity DTx, expanding Lumos Labs from consumer brain training into regulated digital medicine
- Oversaw Lumosity's research collaborations across 20 clinical populations including ADHD, stroke, and traumatic brain injury
- Helped scale Lumosity to over 100 million users globally, supported by 130+ peer-reviewed publications
- Designed the GAMES Study — a 500-participant, 13-site randomized controlled trial that generated the evidence base for FDA clearance

## Latest updates

- **2025-12** — FDA grants 510(k) clearance for LumosityRx (Prismira), the company's prescription digital therapeutic for attention improvement in adults with ADHD ages 22-55, validated by the GAMES Study
- **2023-05** — Appointed Chief Executive Officer of Lumos Labs; predecessor Krishna Kakarala transitions to Executive Chairman

## Links

- Website: https://lumosity.com
- LinkedIn: https://www.linkedin.com/in/bob-schafer-4171554

---

Profile page: https://yespress.io/bob-schafer
Published by YesPress — https://yespress.io
Last updated: 2026-05-13